Form 4: Revolution Medicines CFO Sells Shares Under 10b5-1 Plan

Revolution Medicines' Chief Financial Officer, Jack Anders, exercised stock options and sold 10,000 shares of common stock for a significant profit under a pre-arranged 10b5-1 trading plan.

Summary

• Jack Anders, Chief Financial Officer of Revolution Medicines, Inc. (RVMD), reported transactions involving the company's common stock.
• On November 11, 2025, Anders acquired 10,000 shares of common stock by exercising stock options at a price of $17 per share.
• Concurrently, on November 11, 2025, Anders disposed of 10,000 shares of common stock at a price of $64 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Anders on December 16, 2024.
• Following these transactions, Anders beneficially owns 110,994 shares of common stock, which includes 48,275 restricted stock units.
• The stock option exercised had an exercise price of $17, became exercisable on February 12, 2024, and expires on February 11, 2030.
• After the exercise, 5,418 derivative securities (stock options) remain beneficially owned by Anders.

Sentiment

Score: 5

Explanation: The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which is common for executive compensation and personal financial planning. It does not inherently signal positive or negative company performance.

Positives

• The Chief Financial Officer realized a substantial profit by selling shares at $64 after exercising options at $17, indicating a strong personal return on investment.
• The transaction was conducted under a pre-arranged 10b5-1 trading plan, which demonstrates a planned approach to stock sales rather than an opportunistic reaction to market conditions.

Negatives

• An insider sale, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, although this is a common practice for executive compensation and diversification.

Future Outlook

This filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider transactions are a routine part of executive compensation and personal financial management across all industries, including the biotechnology and pharmaceutical sectors where Revolution Medicines operates. Sales under 10b5-1 plans are common for executives to manage liquidity and diversify their portfolios.

Stakeholder Impact

• Shareholders might observe the insider sale, though the pre-arranged 10b5-1 plan mitigates concerns about opportunistic selling, suggesting the transaction is for personal financial planning rather than a reaction to new company-specific information.

Key Dates

Recommendation

The reported transaction is a pre-scheduled insider sale by the CFO, executed under a 10b5-1 trading plan. Such routine transactions are typically for personal financial management and diversification, and do not usually indicate a change in the company's fundamental prospects or warrant an immediate change in investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Chief Financial Officer, Jack Anders